- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.08. | Glucotrack regains Nasdaq compliance on equity requirement | 1 | Investing.com | ||
| 06.08. | Glucotrack Secures $5.5 Million Financing Through Equity And Convertible Debt | 1 | pulse2.com | ||
| 05.08. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | Glucotrack, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.07. | Glucotrack Gains Slightly on Bridge Financing Deal | - | Baystreet.ca | ||
| 17.07. | Glucotrack completes bridge financing after merger | 1 | Investing.com | ||
| 17.07. | Glucotrack schließt Brückenfinanzierung nach Unternehmenszusammenschluss ab | 2 | Investing.com Deutsch | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 17.07. | GlucoTrack (GCTK) Stock Rallies 16% After Hours: Here's What Is Going On | 2 | Benzinga.com | ||
| 16.07. | Glucotrack completes business combination with Lokahi Therapeutics | 3 | Investing.com | ||
| 15.07. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.07. | Glucotrack combines with Lokahi Therapeutics to become CBGM subsidiary | - | MassDevice | ||
| 14.07. | Glucotrack, Inc.; Lokahi Therapeutics: Glucotrack and Lokahi Therapeutics Complete Strategic Business Combination, Establishing Lokahi-Controlled Public Platform | 297 | GlobeNewswire (Europe) | RUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) today announced the completion of its strategic business combination with Lokahi Therapeutics... ► Artikel lesen | |
| 27.05. | Glucotrack CEO explains tech behind long-term CBGM implant | 12 | MassDevice | ||
| 15.05. | Glucotrack reports Q1 results | 1 | Seeking Alpha | ||
| 14.05. | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 642 | GlobeNewswire (Europe) | Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring... ► Artikel lesen | |
| 14.05. | Glucotrack, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.05. | Glucotrack, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 07.05. | Glucotrack submits long-term implantable CBGM for FDA IDE | - | MassDevice | ||
| 07.05. | Glucotrack beantragt FDA-Zulassung für implantierbaren Blutzuckermonitor | 4 | Investing.com Deutsch |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,050 | 0,00 % | BERENBERG stuft ECKERT & ZIEGLER auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Eckert & Ziegler mit einem Kursziel von 23 Euro auf "Buy" belassen. Die operative Grundleistung des Herstellers radioaktiver... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,065 | -6,07 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| SYNLAB | - | - | EQS-News: SYNLAB: Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients | EQS-News: SYNLAB
/ Key word(s): Miscellaneous
Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
10.08.2026 / 09:00 CET/CEST
The... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,011 | -100,00 % | XFRA 79O: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUGEN MEDICAL DEV.... ► Artikel lesen | |
| HEALWELL AI | 0,493 | +4,01 % | HEALWELL AI: HEALWELL AI's DARWEN AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation | Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN AI as a globally recognized... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| UNIDOC HEALTH | 0,052 | -7,53 % | UniDoc Health Corp.: UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening Platform | Proposed collaboration would combine UniDoc's connected-care infrastructure with Ventripoint's AI-enabled cardiac imaging platform VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / UniDoc Health Corp.... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,255 | +0,40 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| MEDIVOLVE | - | - | Medivolve Inc (2): OSC cites Bharti, Said for disclosure failures | ||
| QUEST DIAGNOSTICS | 210,50 | +0,53 % | Humanity Health Inc.; Quest Diagnostics: Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com | Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platformLONDON, Aug.... ► Artikel lesen | |
| QUIDELORTHO | 12,285 | -4,66 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,800 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,390 | -1,34 % | H.C. Wainwright reiterates Lifeward stock rating on revenue growth | ||
| SENSEONICS | 8,000 | -1,84 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,003 (+1,03 %) liegt der Kurs bei 0,324 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.